Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) announced that 87 of a planned 168 subjects have been enrolled in its registrational Phase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE